Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) on Tuesday, plunged -3.57% from the previous trading day, before settling in for the closing price of $1.4. Within the past 52 weeks, ZNTL’s price has moved between $1.01 and $3.33.
Healthcare Sector giant saw their annual sales slid by -12.89% over the last five years. The company achieved an average annual earnings per share of 21.73%. With a float of $59.50 million, this company’s outstanding shares have now reached $72.25 million.
The firm has a total of 166 workers. Let’s measure their productivity.
Zentalis Pharmaceuticals Inc (ZNTL) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Zentalis Pharmaceuticals Inc is 17.65%, while institutional ownership is 65.06%. The most recent insider transaction that took place on Dec 15 ’25, was worth 9,975,000. In this transaction 10% Owner of this company sold 7,500,000 shares at a rate of $1.33, taking the stock ownership to the 6,459,973 shares. Before that another transaction happened on Apr 30 ’25, when Company’s Director bought 21,000 for $1.40, making the entire transaction worth $29,373. This insider now owns 281,192 shares in total.
Zentalis Pharmaceuticals Inc (ZNTL) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.61 earnings per share (EPS) for the period topping the consensus outlook (set at -0.68) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.41% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Zentalis Pharmaceuticals Inc (ZNTL) is currently performing well based on its current performance indicators. A quick ratio of 7.76 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.08, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.69 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Analysing the last 5-days average volume posted by the [Zentalis Pharmaceuticals Inc, ZNTL], we can find that recorded value of 1.49 million was better than the volume posted last year of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 35.56%.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 16.47%, which indicates a significant increase from 13.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0703 in the past 14 days, which was lower than the 0.1009 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4333, while its 200-day Moving Average is $1.4571. Now, the first resistance to watch is $1.3967. This is followed by the second major resistance level at $1.4433. The third major resistance level sits at $1.4767. If the price goes on to break the first support level at $1.3167, it is likely to go to the next support level at $1.2833. Now, if the price goes above the second support level, the third support stands at $1.2367.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
Market capitalization of the company is 97.54 million based on 72,251K outstanding shares. Right now, sales total 67,430 K and income totals -165,840 K. The company made 0 K in profit during its latest quarter, and -26,690 K in sales during its previous quarter.
